

Docket #: S24-216

Safe, low-tolerance analgesics that target cannabinoid receptor type 1

Researchers at Stanford and WashU developed cannabinoid receptor agonists with distribution mainly to peripheral tissues. Cannabinoid agonists are relevant for treatment of many indications, but current clinical use is limited by a variety of side effects. Structure-based drug design and computational tools were employed to test molecules with unique ligand-receptor interactions, which were then synthesized and tested in a variety of in vitro experiments and models.

Stage of development

In Vitro / In Vivo

Applications

- Treating pain, antinociception
- Peripheral neuropathy

Advantages

- Selectivity
- Efficacy and potency

Innovators

- Ron Dror
- Alex Powers
- Deniz Aydin
- Susruta Majumdar

- Robert Gereau IV
- Vipin Rangari
- Zachariah Bertels
- Richard Slivicki

Licensing Contact

Sam Rubin

Licensing Associate, Life Science

[Email](#)